Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 1 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
72 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
B.C. Oncology from Zaventem, company number BE0629859206, closed financial year 2025 with a result of € -5,396 after tax. For that financial year B.C. Oncology recorded a gross margin of € -3,764 and equity of € 9.5 million. Compared with financial year 2024, the result moved from € -5,208 to € -5,396. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 22, 2026.
€ 9.5 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -5,396
▼ 4 % more loss than in 2024
Profit after tax over the fiscal year.
€ 124
▲ 195% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -4.7 million.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 63
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -4,424 | € -4,110 | € -3,701 | € -3,764 | ▼ € 63 |
| Profit after taxes | € -5,442 | € -5,301 | € -5,208 | € -5,396 | ▼ € 188 |
| Equity | € 9,497,933 | € 9,492,632 | € 9,487,424 | € 9,482,028 | |
| Total debts | € 5,000 | € 8,466 | € 12,594 | € 18,072 | ▲ 43% |
| Cash | € 2,957 | € 1,121 | € 42 | € 124 | ▲ 195% |
| Retained profit | € -4,723,231 | € -4,728,532 | € -4,733,740 | € -4,739,136 | |
| Balance sheet total | € 9,502,933 | € 9,501,098 | € 9,500,018 | € 9,500,100 |
Key figures of B.C. Oncology, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to B.C. Oncology?
What happened at B.C. Oncology in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- ADP VENTURES BV stepped down as director. NBB
- WEPAVEN BV stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 5,396. Source: NBB ↗
- MARA CONSULTING BV stepped down as director. NBB
- ADP VENTURES BV became a director. NBB
- MARA CONSULTING BV became a director. NBB
- WEPAVEN BV became a director. NBB
- New establishment in Zaventem. KBO
In short
From € 5,442 loss in 2022 to € 5,396 loss in 2025.
A new publication or filing at B.C. Oncology? We notify you, reason included.
Follow B.C. OncologyDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
It owns 10.9% of HIGHLIGHT THERAPEUTICS SL itself.
Directors
According to the 2025 annual accounts
Director · represented by Matthias DE WITTE
Also active at: DROIA Facility Services, Aura Invest, Metaptys, DINVEI
since 2021 · until 2026
Director · represented by Alexander DEPAUW
Also active at: DROIA Facility Services, Aura Invest, Metaptys, DINVEI
since 2026 · until 2031
Managing director · represented by Janwillem NAESENS
Also active at: DROIA Facility Services, Aura Invest, DINVEI, DCIM
since 2021 · until 2027
Establishments
Establishment units
Physical locations of this company
Da Vincilaan 1
1930 Zaventem
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 72 companies are registered at this address.
All companies at this address →ALFA LAVAL BENELUX
€ 4.8 million gross margin · 2025
Association of Belgian Travel Organisers
ORTHO - CLINICAL DIAGNOSTICS
€ 12.7 million revenue · 2025
FIRST STOP EUROPE
€ 8 million revenue · 2025
JOMIROU
€ -17,491 gross margin · 2024
+67 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0629.859.206
- VAT number
- BE 0629.859.206
- Registered office
- Da Vincilaan 1, 1930 Zaventem
- Names & denominations
- B.C. Oncology
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 7 May 2015
- Peppol
- Not registered